266 related articles for article (PubMed ID: 9737389)
1. Safety of biological products prepared from mammalian cell culture. In-process testing for viral agents.
Dev Biol Stand; 1998; 93():130-1. PubMed ID: 9737389
[No Abstract] [Full Text] [Related]
2. Safety of biological products prepared from mammalian cell culture. Detecting viruses in cell banks.
Dev Biol Stand; 1998; 93():129. PubMed ID: 9737388
[No Abstract] [Full Text] [Related]
3. Safety of biological products prepared from mammalian cell culture. Testing source materials.
Dev Biol Stand; 1998; 93():131-3. PubMed ID: 9737390
[No Abstract] [Full Text] [Related]
4. Safety of biological products prepared from mammalian cell culture. Host-cell proteins.
Dev Biol Stand; 1998; 93():139-40. PubMed ID: 9737394
[No Abstract] [Full Text] [Related]
5. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline.
Dev Biol Stand; 1998; 93():177-201. PubMed ID: 9737396
[No Abstract] [Full Text] [Related]
6. Safety of biological products prepared from mammalian cell culture. DNA.
Dev Biol Stand; 1998; 93():136-8. PubMed ID: 9737393
[No Abstract] [Full Text] [Related]
7. Safety of biological products prepared from mammalian cell culture. Karyology.
Dev Biol Stand; 1998; 93():134-6. PubMed ID: 9737392
[No Abstract] [Full Text] [Related]
8. Viral safety of biological products and the concept of validation.
Horaud F
Dev Biol Stand; 1996; 88():19-24. PubMed ID: 9119135
[No Abstract] [Full Text] [Related]
9. Issues related to harmonization of testing requirements for viral safety.
Hayakawa T
Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
[TBL] [Abstract][Full Text] [Related]
10. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (requirements for biological substances No 50).
Dev Biol Stand; 1998; 93():141-71. PubMed ID: 9737395
[No Abstract] [Full Text] [Related]
11. Process scale considerations in evaluation studies and scale-up.
Walter JK; Werz W; Berthold W
Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
[TBL] [Abstract][Full Text] [Related]
12. Validation of virus removal in large scale purification processes.
Fritsch E
Dev Biol Stand; 1992; 76():239-48. PubMed ID: 1478342
[No Abstract] [Full Text] [Related]
13. Relationship between nature and source of risk and process validation.
Berthold W; Werz W; Walter JK
Dev Biol Stand; 1996; 88():59-71. PubMed ID: 9119164
[No Abstract] [Full Text] [Related]
14. A comparison of methods for the estimation of retroviral burden.
Bierley ST; Raineri R; Poiley JA; Morgan EM
Dev Biol Stand; 1996; 88():163-5. PubMed ID: 9119132
[TBL] [Abstract][Full Text] [Related]
15. Process evaluation for biopharmaceuticals: what is appropriate in process evaluation?
Lubiniecki AS; McAllister PR; Smith TM; Shadle PJ
Dev Biol Stand; 1996; 88():309-15. PubMed ID: 9119154
[No Abstract] [Full Text] [Related]
16. Safety of biological products prepared from mammalian cell culture. Bovine spongiform encephalopathy and other non-viral transmissible agents.
Dev Biol Stand; 1998; 93():133-4. PubMed ID: 9737391
[No Abstract] [Full Text] [Related]
17. Process changes and their effect on process evaluation for viral clearance.
Marcus-Sekura C
Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
[TBL] [Abstract][Full Text] [Related]
18. Survey of manufacturers and developers of cell culture-derived products for evidence of adventitious contamination.
Lubiniecki AS
Dev Biol Stand; 1996; 88():195-7. PubMed ID: 9119136
[No Abstract] [Full Text] [Related]
19. Introduction to the issues: new potential contaminants and other exogenous agents.
Albrecht P
Dev Biol Stand; 1992; 76():255-8. PubMed ID: 1478344
[No Abstract] [Full Text] [Related]
20. Minimum safety requirements for preclinical testing.
Dorner F; Barrett PN; Schwartz HP; Eibl H
Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
